PDT Partners LLC Makes New Investment in Supernus Pharmaceuticals, Inc. $SUPN

Posted by George Bondi on Aug 27th, 2026

PDT Partners LLC acquired a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) in the 2nd quarter, Holdings Channel reports. The fund acquired 25,858 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,203,000.

Several other large investors have also modified their holdings of SUPN. Rockefeller Capital Management L.P. grew its position in shares of Supernus Pharmaceuticals by 354.8% in the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock valued at $42,000 after buying an additional 660 shares during the last quarter. Torren Management LLC acquired a new stake in Supernus Pharmaceuticals during the 4th quarter worth $49,000. EverSource Wealth Advisors LLC purchased a new stake in Supernus Pharmaceuticals in the second quarter valued at $51,000. Hantz Financial Services Inc. lifted its position in Supernus Pharmaceuticals by 73.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock valued at $54,000 after acquiring an additional 458 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Supernus Pharmaceuticals in the second quarter valued at $55,000.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on SUPN shares. Zacks Research raised Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 6th. Wall Street Zen cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Cantor Fitzgerald raised their price target on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $62.83.

View Our Latest Stock Report on Supernus Pharmaceuticals

Supernus Pharmaceuticals Trading Down 1.1%

Shares of SUPN opened at $44.88 on Thursday. The stock’s 50 day moving average is $46.83 and its two-hundred day moving average is $48.74. Supernus Pharmaceuticals, Inc. has a twelve month low of $42.45 and a twelve month high of $59.68. The firm has a market capitalization of $2.61 billion, a PE ratio of -23.37, a P/E/G ratio of 0.84 and a beta of 0.56.

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) last issued its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The business had revenue of $219.06 million for the quarter, compared to analysts’ expectations of $205.31 million. During the same period last year, the company posted $0.40 earnings per share. The business’s quarterly revenue was up 32.4% on a year-over-year basis. On average, sell-side analysts predict that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current year.

Supernus Pharmaceuticals Company Profile

(Free Report)

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.